Research Report
Dr. Jonathan Aschoff (12/14/2023)
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.